Did you know that there are 10 JPIs (Joint Programming Initiatives) addressing societal challenges, from climate change to neurodegenerative diseases, through coordinated research and innovation in Europe? Watch the video below, created in honour of the tenth anniversary of JPIs, to find out more about how they are tackling some of the biggest issues facing our society.
From today, funders and researchers can access a database containing survey information spanning three decades-worth of global neurodegenerative disease research funding.
The new, expanded online database is the result of a large-scale mapping exercise of neurodegenerative disease research investments and infrastructure across Europe, Australia and Canada – all member countries of the EU Joint Programme for Neurodegenerative Diseases (JPND). It follows a smaller-scale survey completed in 2011.
Providing a snapshot of public and not-for-profit investment in the area, the new data captured in 2016 covers research funding and resources recorded as active on 1 January 2016.
Together with the existing 2011 data, the investments span a 28-year period, from 2002 to 2030. Combined with projects from the first exercise, the database now indexes more than 3,100 projects and resources.
Analysis of the data, published in an accompanying report, reveals that annual neurodegenerative research spending has increased by 34% across JPND since 2011, from €370 million up to €494 million.
The aim of this expanded, interactive resource is to share funding information, promote new collaborations and inform strategy, ultimately supporting scientific progress in the neurodegenerative disease area.
The latest 2016 mapping exercise captures 2,672 projects, ranging from large multinational research programmes to small investments and fellowship awards. It covers seven new JPND members and data from partners in 27 different countries, including JPND transnational awards for the first time.
Visitors can use the database to explore what type of research has been funded and look at profiles of past and current investments by multiple funders or within specific countries. Research organisations may find it useful to draw on the information as a basis for coordinating funding strategies and preventing duplication.
To increase the global reach of the data, it will also be displayed in the International Alzheimer’s and Related Dementias Research Portfolio (IADRP) database. This follows a new partnership between JPND, the U.S. National Institute on Aging (NIA), part of the National Institutes of Health (NIH), and the Alzheimer’s Association (AA). Reciprocally, relevant research from the NIH will be accessible via the JPND database later this year.
About the EU Joint Programme on Neurodegenerative Disease Research (JPND)
JPND brings together 30 countries to accelerate discovery by aligning research priorities, approaches and programmes. This has resulted in the creation of the largest global collaboration in the field and represents an innovative approach to finding causes, developing cures and identifying appropriate ways to care for people living with neurodegenerative diseases. To learn more about JPND, visit www.jpnd.eu.
Two major research funding entities in the EU and US are joining forces for the first time to optimise and harmonise research into neurodegenerative diseases. The EU Joint Programme on Neurodegenerative Disease Research (JPND) and the U.S. National Institute on Aging (NIA), part of the National Institutes of Health (NIH) announced today the creation of a new cross-initiative action to link and support collaborations between researchers working in the field.
NIH and JPND ran separate calls for proposals in 2017 to investigate common mechanisms and pathways in neurodegenerative diseases. With this joint action, researchers supported under the JPND call are invited to team up with researchers supported under the NIH call, and vice versa, to propose joint activities such as common workshops, data exchanges and pilot experiments. These activities will add value to the science being undertaken in ongoing projects by accelerating knowledge transfer between research groups.
“Collaboration is the key to progressing our understanding of the biological underpinnings of neurodegenerative disease,” said JPND Chair Professor Philippe Amouyel. “These awards will offer NIH and JPND researchers the opportunity to more systematically and efficiently connect and share knowledge, tools and data. They will enhance current investigations into the fundamental mechanisms of neurodegenerative diseases while also planting the seeds of future collaboration.”
“This is a crucial time of expanding global interest and support for neurodegenerative disease research,” said Dr. Eliezer Masliah, director of the NIA’s Division of Neuroscience. “In our connected age, breakthroughs in Alzheimer’s, vascular dementia, Lewy body disease, frontotemporal dementia and other neurological disorders require teamwork, and we look forward to strengthening the scientific connections between talented researchers across the EU and the US.”
Four research projects were supported under NIH’s call, “PAS17-028 Common Mechanisms and Interactions Among Neurodegenerative Diseases (R01)”. JPND’s call for “Multinational research projects for Pathway Analysis across Neurodegenerative Diseases” resulted in the support of ten research consortia, covering a range of diseases including Alzheimer’s and Parkinson’s disease.
About the EU Joint Programme on Neurodegenerative Disease Research (JPND): JPND brings together 30 countries to accelerate discovery by aligning research priorities, approaches and programmes. This has resulted in the creation of the largest global collaboration in the field and represents an innovative approach to finding causes, developing cures and identifying appropriate ways to care for people living with neurodegenerative diseases. To learn more about JPND, visit www.jpnd.eu.
About the National Institute on Aging: The NIA leads the federal government effort conducting and supporting research on aging and the health and well-being of older people. The NIA is designated as the lead NIH institute for information on Alzheimer’s disease. It provides information on age-related cognitive change and neurodegenerative disease, including participation in clinical studies, specifically on its Alzheimer’s website.
The database, which was first made available to the community in 2017, is a unique collection aimed at presenting and fostering scientific discussion around the experimental models currently available to study Parkinson’s disease.
The database is continuously updated to reflect developments from the scientific literature and is a major effort by JPND to help researchers in the field. Together with an exhaustive description of each model and the studies that have already been done, there is a section for comments. You are welcome to add your comments to any of the models you have had experience with or to present alternative models.
We hope that you will join this growing community of scientists. To consult the database and add your contributions, please visit: https://www.neurodegenerationresearch.eu/models-for-parkinsons-disease/.
If you’d like any additional information, don’t hesitate to contact us directly at [email protected].
The EU Joint Programme – Neurodegenerative Disease Research (JPND) has awarded funding to ten research projects to perform new network analyses in order to better understand the common underlying mechanisms involved in neurodegenerative diseases.
Previous research has already shown that similar molecular pathways are relevant in different neurodegenerative and other chronic diseases. With this funding, JPND enables ten multidisciplinary consortia, made up of research teams in 14 countries, to further scrutinise these pathways. This combined analysis of diseases across traditional clinical boundaries, technologies and disciplines could lead to new scientific insights, a re-definition of clinical phenotypes and, ultimately, innovative approaches in the treatment of neurodegenerative diseases.
“The recent failures of a number of clinical trials for Alzheimer’s disease make clear that we are still far from fully understanding the biological underpinnings of neurodegenerative diseases,” said JPND Chair Professor Philippe Amouyel. “The ten world-class consortia selected for funding in this call bring together skills and knowledge from across different disciplines and countries. They are poised to open collaborative new investigations into the fundamental mechanisms that we see in multiple diseases but that we don’t yet understand. We hope that this research will result in new hypotheses that could lead to the next generation of therapeutic approaches.”
The ten projects were recommended for funding by an independent, international Peer Review Panel based on scientific excellence.
Click on the links below to learn more about each project supported under JPND’s 2017 Pathway Analysis call.
BRAIN-MEND: Biological Resource Analysis to Identify New Mechanisms and phenotypes in Neurodegenerative Diseases
Ammar Al-Chalabi, King’s College London, King’s Clinical Neuroscience Institute, London, UK
Naomi Wray, University of Queensland, Brisbane, QLD, Australia
Gilbert Bensimon, Centre Hospitalier Universitaire de Nîmes, Nîmes, France
Orla Hardiman, Trinity College Dublin, Ireland
Adriano Chio, University of Turin, Italy
Jan Veldink, University Medical Center, Utrecht, Netherlands
EpiAD: Effect of early and adult-life stress on the brain epigenome: relevance for the occurrence of Alzheimer’s Disease and Diabetes-related dementia
Johannes Gräff, Brain Mind Institute, School of Life Sciences, Ecole Polytechnique Fédérale Lausanne, Switzerland
Froylan Calderon de Anda, Center for Molecular Neurobiology Hamburg, Hamburg, Germany
Ana Frank-Garcia, Department of Neurology, University Hospital La Paz, Madrid, Spain
Agnieszka Basta-Kaim, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
HEROES: The locus coeruleus: at the crossroad of dementia syndromes
Mara Dierssen, Instituto Hospital del Mar de Investigaciones Mèdicas (IMIM), Barcelona, Spain
Yann Herault, Institut de Génétique Biologie Moléculaire et Cellulaire (IGBMC), Illkirch-Graffenstaden, France
Marie-Claude Potier, Institut du Cerveau et de la Moëlle Epinière (ICM), Paris, France
Peter Paul De Deyn, University Medical Center Groningen (UMCG), The Netherlands
André Strydom, University College London (UCL), United Kingdom
localMND: Common architecture of local proteome, transcriptome and translatome across Motor Neuron disorders
Marina Chekulaeva, Berlin Institute for Medical Systems Biology, Berlin, Germany
Igor Ulitsky, Weizmann Institute of Science, Rehovot, Israel
Vincenzo La Bella, Department of Experimental BioMedicine and Clinical Neurosciences, University of Palermo, Palermo, Italy
Erik Storkebaum, Department of Molecular Neurobiology, Radboud University, Nijmegen, the Netherlands
LODE: Loss of neurotrophic factors in neurodegenerative Dementias: Back to the crossroads of proteins
Roberta Ghidoni, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
Giuseppe Di Fede, Foundation IRCCS Carlo Besta Neurological Institute, Milan, Italy
Katharina Landfester, Max Planck Institute for Polymer Research, Mainz, Germany
Maria Grazia Spillantini, University of Cambridge, Cambridge, UK
NEURONODE: Systems Analysis of Key Nodes in Neurodegenerative Diseases
Peter McCormick, Queen Mary University of London, United Kingdom
Nicolas Locker, University of Surrey, United Kingdom
Carl Ernst, McGill University, Canada
Stephane Lefrancois, Institut National de la Recherche Scientifique, Laval, Canada
Andreas Schuppert, RWTH Aachen University, Germany
Andrew Ewing, University of Gothenburg, Sweden
Protest-70: Protecting protein homeostasis in synucleinopathies and tauopathies by modulating the Hsp70/co-chaperone network
Carmen Nußbaum-Krammer, Center for Molecular Biology of Heidelberg University (ZMBH) and German Cancer Research Center (DKFZ), Heidelberg, Germany
Bernd Bukau, Center for Molecular Biology of Heidelberg University (ZMBH) and German Cancer Research Center (DKFZ), Heidelberg, Germany
Ronald Melki, Paris-Saclay Institute of Neuroscience, CNRS, France
Harm Kampinga, Faculty of Medical Sciences, University of Groningen, Netherlands
Christian Hansen, Faculty of Medicine, Lund University, Sweden
RNA-NEURO: Systems Analysis of novel small non-coding RNA in neuronal stress responses: towards novel biomarkers and therapeutics for neurodegenerative disorders
Jochen Prehn, Royal College of Surgeons in Ireland, RCSI Centre for Systems Medicine, Dublin, Ireland
Ruth Slack, University of Ottawa, Canada
Jørgen Kjems, Aarhus University, Denmark
Mark Helm, University of Mainz, Germany
Giovanni Nardo, IRCCS-Mario Negri Institute, Milan, Italy
Michael Adriaan van Es, University Medical Center, Utrecht, Netherlands
TransNeuro: Altered mRNA translation as a pathogenic mechanism across neurodegenerative diseases
Erik Storkebaum, Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, Netherlands
Nahum Sonenberg, McGill University, Montreal, Canada
Marie-Christine Chartier-Harlin, Inserm UMRS1172, Lille, France
Erin Schuman, Max Planck Institute for Brain Research, Frankfurt, Germany
Kobi Rosenblum, University of Haifa, Haifa, Israel
Giovanna Mallucci, University of Cambridge, Cambridge, UK
TransPathND: Intraneuronal transport-related pathways across neurodegenerative diseases
Michel Simonneau, Laboratoire Aimé Cotton, ENS Paris-Saclay, Orsay, France
Ronald Melki, Paris-Saclay Institute of Neuroscience, CNRS, Gif-sur-Yvette, France
August B. Smit, Center for Neurogenomics and Cognitive Research, VU University Amsterdam, Netherlands
Nicolas Le Novere, Babraham Institute, Cambridge, United Kingdom
The UK Dementia Research Institute (UK DRI) is now recruiting an associate director to lead its care and technology programme. Candidates should have an exciting vision for how patient-focused research can lead to a significantly improved quality of life for people affected by dementia.
With a budget of £20 million, the new care and technology programme will be fully integrated into the wider institute, will benefit from its considerable resources and networks and, crucially, will embrace novel technologies and interdisciplinary approaches.
The deadline to apply is 17 April 2018.
To learn more and download the recruitment pack, please visit the UK DRI website.
The U.S. Alzheimer’s Association is now accepting letters of intent (LOI) for a new programme called GAAIN Exploration to Evaluate Novel Alzheimer’s Queries (GEENA-Q).
The Global Alzheimer’s Association Interactive Network (GAAIN) is a big data platform for cohort discovery and data exploration focused on Alzheimer’s disease and dementia. GAAIN provides tools that allow researchers to explore diverse clinical, health factor, genetic, and imaging datasets from data partners around the world. It currently has nearly 500,000 unique clinical records from nearly 30 clinical studies.
GEENA-Q will stimulate researchers to interrogate the federated GAAIN network for new discoveries in Alzheimer’s research. Applications are encouraged from research laboratories and teams around the world.
LOI must be received by 5:00 PM ET, on April 4, 2018.
How should academia and industry collaborate to generate new diagnostic tools and therapies for neurodegenerative diseases?
At a workshop in Turin in October 2017, JPND brought together some 20 representatives from academia and the private sector to address this question and to lay the foundations for future exchanges and collaborations.
In a series of frank and lively discussion sessions, participants offered their views on the scientific areas and activities where potential exists for improved collaboration and alignment. Participants represented a broad range of sectors, including pharma, diagnostics, imaging, medical devices, and healthcare providers, and about half of the private-sector attendees came from small and medium-sized enterprises (SMEs).
During the discussions and in responses gathered by questionnaire, the three most important areas identified for potential collaboration – based on the scientific priorities of the JPND Research Strategy – were Developing therapies, preventive strategies and interventions, followed by Disease mechanisms and models and Origins of neurodegenerative diseases.
Participants identified science exchange programmes and infrastructure sharing as specific activities around which JPND and industry scientists could work together in the future. Other ideas identified from the brainstorming included organising a meeting for industry scientists focused on JPND research findings as well as inviting company scientists to join the review board for JPND calls. Direct participation in JPND calls was also encouraged, for example there could be a call to enable scientists who had developed promising products to interact with SMEs that specialized in product development.
JPND’s activities and new tools, including the Experimental Models for Parkinson’s Disease Database and the Global Cohort Portal, were also presented as part of the workshop.
The half-day meeting, which took place as part of the annual Meet in Italy for Life Sciences event, represented a first step toward improved engagement with industry and SMEs, and the outputs will be further analysed to improve JPND’s ongoing and future strategy for engagement with industry.
To mark the end of the FlySMALS consortium, which was funded in the 2013 JPND Cross-Disease Analysis call, project partners are now organising a workshop on integrative approaches in neurodegeneration.
The workshop, which will take place in Lisbon, Portugal, from 21-23 June 2018, aims to disseminate and integrate the results of the research consortium with state-of-the-art research in the field, promoting the joint presentation and discussion of relevant research topics by a panel of international experts, including members of other consortia funded through the same JPND call.
The programme targets a broad audience of basic, experimental, computational and clinical scientists, in the spirit of the JPND Cross-Disease Analysis call, aiming to:
- promote the analysis of diseases across traditional clinical boundaries
- combine fundamental, pre-clinical and clinical experimental approaches with computational approaches
- re-define clinical phenotypes and new approaches in the treatment of neurodegenerative diseases
- identify commonalities and differences in molecular pathways underlying neurodegenerative diseases
The workshop will bring together 20 invited speakers and 50 registered participants, providing opportunities for dynamic interactions and exchange of expertise across areas. Participants will be able to present their work at a poster session and in short talks from selected abstracts.
To view the full scientific programme and register, please visit the workshop website: http://bit.ly/IANeuroD.
The Weston Brain Institute is now accepting applications to its Rapid Response: Ireland, Netherlands, UK 2018 (Fluid Biomarkers) program.
This initiative aims to provide seed funding, without requirement for preliminary data, to support high-risk, high-reward, translational research on novel biomarkers detected in patient-derived fluids (e.g., blood, CSF, saliva, stool).
Principal Applicants must be at eligible institutions located in Ireland, the Netherlands, or the UK.
The deadline to submit a Letter of Intent is Monday, 23 April, 2018, 4:00pm BST.
More information is available on the program website.